MedPath

Liafensine

Generic Name
Liafensine
Drug Type
Small Molecule
Chemical Formula
C24H22N4
CAS Number
1198790-53-2
Unique Ingredient Identifier
R34ID086Z6
Background

Liafensine is under investigation in clinical trial NCT00892840 (Multiple-Ascending Dose Study).

Clinical Trials
Related News

A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD

Phase 2
Completed
Conditions
Treatment Resistant Depression
Interventions
Drug: Placebo
First Posted Date
2021-11-09
Last Posted Date
2025-05-15
Lead Sponsor
Denovo Biopharma LLC
Target Recruit Count
197
Registration Number
NCT05113771
Locations
🇺🇸

University of Alabama at Birmingham, Huntsville, Alabama, United States

🇺🇸

Collaborative Neuroschience Research, LLC, Garden Grove, California, United States

🇺🇸

Behavioral Research Specialists, LLC, Glendale, California, United States

and more 40 locations

Japanese Phase 1 Multiple Ascending Dose (MAD) Study

Phase 1
Completed
Conditions
Depression
Interventions
First Posted Date
2011-07-18
Last Posted Date
2013-06-10
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
57
Registration Number
NCT01396252
Locations
🇯🇵

Local Institution, Taito-Ku, Tokyo, Japan

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

First Posted Date
2011-06-08
Last Posted Date
2015-10-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
976
Registration Number
NCT01369095
Locations
🇺🇸

Mclean Hospital, Belmont, Massachusetts, United States

🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

🇺🇸

Pacific Clinical Research Medical Group, Orange, California, United States

and more 45 locations

Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Phase 2
Terminated
Conditions
Depression
Interventions
First Posted Date
2011-05-27
Last Posted Date
2015-10-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
789
Registration Number
NCT01361555
Locations
🇺🇸

Red Oak Psychiatry Associates, Pa, Houston, Texas, United States

🇺🇸

California Neuroscience Research Medical Group, Inc., Sherman Oaks, California, United States

🇺🇸

Schuster Medical Research Institute, Sherman Oaks, California, United States

and more 83 locations

Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression

Phase 2
Completed
Conditions
Depression
Interventions
Drug: Placebo matching with Duloxetine
First Posted Date
2011-03-07
Last Posted Date
2015-10-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
889
Registration Number
NCT01309945
Locations
🇺🇸

Univ Of Penn, Philadelphia, Pennsylvania, United States

🇺🇸

Psychiatric Consultants, Pc, Franklin, Tennessee, United States

🇺🇸

Pacific Clinical Research Medical Group, Upland, California, United States

and more 45 locations

Single Dose Study of BMS-820836

Phase 1
Completed
Conditions
Depression
Interventions
Drug: Placebo
First Posted Date
2009-08-25
Last Posted Date
2011-01-25
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
68
Registration Number
NCT00964912
Locations
🇨🇦

Local Institution, Toronto, Ontario, Canada

Multiple-Ascending Dose Study

Phase 1
Completed
Conditions
Depression
Interventions
Drug: Placebo
First Posted Date
2009-05-05
Last Posted Date
2011-02-11
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
57
Registration Number
NCT00892840
Locations
🇸🇪

Local Institution, Uppsala, Sweden

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy